Smurf-1-IN-3
Smurf-1-IN-3 is a selective Smurf-1 inhibitor with an IC50 value of 2.2 nM. Smurf-1-IN-3 can be used for the research of pulmonary arterial hypertension.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1825312-08-0
- Formule: C25H27F3N4O4
- Masse moléculaire:504.50
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
In Vitro
Smurf-1-IN-3 (Compound 45) (45 min) potently inhibits recombinant Smurf-1 autoubiquitinylation with an IC50 of 2.2 nM[1].
Smurf-1-IN-3 (6.75 nM-22.5 μM) stabilizes Smurf-1 protein in tetracycline-inducible HEK293 cells, confirming cellular inhibition of Smurf-1 activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1825312-08-0
-
Masse moléculaire 504.50
-
Formule C25H27F3N4O4
-
SMILES
O=C(C1=NOC2=C1CCCC3=C2C=CC(OC(F)(F)F)=C3)NC4=C(C)N(C)N(C5CCCCC5)C4=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)